Published in Gut on September 01, 2003
Immunomodulatory functions of type I interferons. Nat Rev Immunol (2012) 3.73
Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest (2005) 3.36
Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med (2006) 1.76
Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol (2008) 1.52
Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis (2008) 1.28
Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis. Gut (2005) 1.19
Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production. Gut (2010) 1.17
Type I interferons maintain Foxp3 expression and T-regulatory cell functions under inflammatory conditions in mice. Gastroenterology (2012) 1.02
STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res (Phila) (2010) 0.92
Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol (2007) 0.91
Activation of interferon regulatory factor-3 via toll-like receptor 3 and immunomodulatory functions detected in A549 lung epithelial cells exposed to misplaced U1-snRNA. Nucleic Acids Res (2009) 0.91
Type I interferons in bacterial infections: taming of myeloid cells and possible implications for autoimmunity. Front Immunol (2014) 0.91
The role of type I interferons in intestinal infection, homeostasis, and inflammation. Immunol Rev (2014) 0.89
Interfering with interferons in inflammatory bowel disease. Gut (2006) 0.87
Influenza Virus Affects Intestinal Microbiota and Secondary Salmonella Infection in the Gut through Type I Interferons. PLoS Pathog (2016) 0.86
Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci (2007) 0.86
Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol (2009) 0.85
Illuminating the role of type I IFNs in colitis. J Clin Invest (2005) 0.81
Ulcerative colitis: conservative management and long-term effects. Langenbecks Arch Surg (2004) 0.81
Rebamipide suppresses TLR-TBK1 signaling pathway resulting in regulating IRF3/7 and IFN-α/β reduction. J Clin Biochem Nutr (2011) 0.80
Lessons from type I interferons in ulcerative colitis. Gut (2011) 0.80
Sequestering HMGB1 via DNA-conjugated beads ameliorates murine colitis. PLoS One (2014) 0.78
Plasmacytoid dendritic cell-derived IFNα modulates Th17 differentiation during early Bordetella pertussis infection in mice. Mucosal Immunol (2015) 0.77
Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis (2016) 0.76
Type I and III Interferon in the Gut: Tight Balance between Host Protection and Immunopathology. Front Immunol (2017) 0.75
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med (1987) 7.73
Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol (1995) 2.90
Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol (1995) 2.71
Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med (1989) 2.55
Ulcerative colitis. Lancet (2002) 2.10
Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ (1992) 1.94
An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol (2001) 1.88
Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology (1996) 1.85
Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol (1995) 1.72
A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology (1975) 1.69
Human natural killer cell activity is augmented by interferon via recruitment of 'pre-NK' cells. Scand J Immunol (1979) 1.54
Cytokine production in patients with inflammatory bowel disease. Gut (1992) 1.50
Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol (1996) 1.15
Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology (1999) 1.13
Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology (1996) 1.04
Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther (2002) 1.00
Cytokines in Crohn's colitis. Am J Surg (1995) 1.00
Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig Dis (1995) 0.97
Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials. Eur J Neurol (2000) 0.96
Suppressor T cell activation by human leukocyte interferon. J Immunol (1983) 0.92
In vivo effects of chicken interferon-gamma during infection with Eimeria. J Interferon Cytokine Res (1997) 0.92
Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease. J Pediatr Gastroenterol Nutr (1995) 0.91
Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). Hepatogastroenterology (1998) 0.84
Inhibition of interferon-gamma-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocytoma cells. Definition of cis-element. J Biol Chem (1993) 0.82
Role of interferon-gamma in lung inflammation following cecal ligation and puncture in rats. Shock (1999) 0.81
Role of protein kinase C in induction of gene expression and inhibition of cell proliferation by interferon alpha. Eur J Biochem (1992) 0.80
Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a. J Interferon Cytokine Res (1997) 0.80
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet (2001) 7.27
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut (2004) 5.32
Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol (1993) 4.68
Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med (1995) 4.56
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut (2010) 4.50
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut (2008) 4.41
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 4.08
Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet (2000) 3.52
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut (2009) 3.50
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut (2008) 3.14
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 3.00
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 2.81
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology (1999) 2.80
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78
Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut (1984) 2.70
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J (2010) 2.56
Current status of genetics research in inflammatory bowel disease. Genes Immun (2005) 2.29
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther (2015) 2.25
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut (2007) 2.22
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology (1997) 2.18
Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology (1998) 2.15
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology (1996) 2.08
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol (2001) 2.06
Predicting relapse in Crohn's disease: a biopsychosocial model. Gut (2008) 2.01
TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry (2010) 2.00
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer. Gut (1980) 1.95
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 1.95
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology (1995) 1.90
Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry (2009) 1.89
Definition of polymorphisms and haplotypes in the interleukin-12B gene: association with IL-12 production but not with Crohn's disease. Genes Immun (2004) 1.89
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther (2004) 1.87
Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology (1998) 1.86
Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology (1997) 1.84
Postural dependency of the cerebral venous outflow. Lancet (2000) 1.81
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut (2008) 1.75
In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology (1998) 1.74
Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology (1998) 1.73
Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol (1997) 1.69
Predictors of PTSD in injured trauma survivors: a prospective study. Am J Psychiatry (1996) 1.68
Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. Mol Psychiatry (2011) 1.65
Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther (2012) 1.64
COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. Br J Cancer (2009) 1.62
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther (2004) 1.62
An integrated system for high throughput TaqMan based SNP genotyping. Bioinformatics (2001) 1.61
Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol (1998) 1.60
Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc (1999) 1.59
Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet (1999) 1.57
Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. Eur J Nucl Med (1998) 1.56
Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypes. Eur Respir J (2010) 1.55
Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's disease. Med Decis Making (2000) 1.51
The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun (2007) 1.50
Enhancement of macrophage candidacidal activity by interferon-gamma. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors. J Clin Invest (1993) 1.50
Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet (1990) 1.49
Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther (1998) 1.47
Influence of nutritional substrates on the formation of volatiles by the fecal flora. Gastroenterology (1991) 1.45
IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol (2000) 1.45
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther (2005) 1.45
Nutritional effects of surgical and medical treatment for short bowel syndrome. JPEN J Parenter Enteral Nutr (2001) 1.44
A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol (2002) 1.44
Endoscopic ultrasound of the colon for the differentiation of Crohn's disease and ulcerative colitis in comparison with healthy controls. Aliment Pharmacol Ther (2014) 1.43
Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther (2014) 1.43
Genome-wide survey implicates the influence of copy number variants (CNVs) in the development of early-onset bipolar disorder. Mol Psychiatry (2011) 1.43
Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. Gut (1995) 1.42
Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr (1999) 1.42
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 1.41
Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis (2001) 1.41
Controlled trial of YAG laser treatment of upper digestive hemorrhage. Gastroenterology (1982) 1.39
Inferior subluxation of the humeral head: the drooping shoulder. Radiology (1971) 1.39
Helicobacter pylori infection and growth delay in older children. Arch Dis Child (1997) 1.39
Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies. Aliment Pharmacol Ther (2007) 1.39
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol (2002) 1.38
Long term results of treatment of vascular malformations of the gastrointestinal tract by neodymium Yag laser photocoagulation. Gut (1985) 1.38
Letter: dry blood spots for anti-TNF treatment monitoring in IBD. Aliment Pharmacol Ther (2013) 1.37
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut (2006) 1.36
The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther (2005) 1.34
The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther (2004) 1.33
Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future. Aliment Pharmacol Ther (2013) 1.32
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther (2013) 1.32